Dyne Therapeutics, Inc.

Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares of its common stock at $20.50 per share, expecting gross proceeds of $375.15 million. The company also granted underwriters an option to purchase up to an additional 2.745 million shares. Net proceeds are estimated to be $352.1 million, potentially reaching $405.0 million if the option is fully exercised. These funds, combined with existing capital and a recent $50 million loan tranche, are projected to extend the company's cash runway into the second quarter of 2028.

Dyne Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at $20.50 per share. The offering is expected to generate gross proceeds of $375,150,000 for the company. Dyne has also granted the underwriters an option to purchase up to an additional 2,745,000 shares. The offering is anticipated to close around July 23, 2026.

Dyne Therapeutics, Inc. announced the commencement of an underwritten public offering of $300,000,000 of its common stock. The company also plans to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares. All shares in the offering will be sold by Dyne, with Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James serving as joint book-running managers.

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for zeleciment rostudirsen (DYNE-251) for Duchenne muscular dystrophy. The FDA granted Priority Review and set a PDUFA target action date of January 21, 2027. The company continues to expect a potential U.S. launch in the first quarter of 2027, contingent on approval.

Dyne Therapeutics announced that the FDA has accepted for review its Biologics License Application (BLA) for zeleciment rostudirsen (z-rostudirsen) for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The FDA granted Priority Review and set a PDUFA target action date of January 21, 2027. The company anticipates a potential U.S. launch in Q1 2027, assuming approval, marking significant progress in its goal to provide functional improvement for DMD patients.

Dyne Therapeutics, Inc. announced the election of Barry E. Greene as a Class I director to its Board of Directors, effective June 22, 2026. Mr. Greene will serve until the 2027 Annual Meeting of Stockholders and has been determined to be an "independent" director. As part of his compensation, he received an option to purchase 57,463 shares of common stock at an exercise price of $20.87 per share, vesting over three years, and will receive annual cash compensation of $45,000.

Dyne Therapeutics, Inc. announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings over three decades of biopharmaceutical industry experience, including leadership roles at Sage Therapeutics and Alnylam Pharmaceuticals, with a strong track record in commercialization and scaling innovative companies. This strategic addition aims to strengthen the board as Dyne approaches a planned transformation into a commercial biotechnology company, anticipating potential product launches and revenue generation.

Dyne Therapeutics, Inc. entered into a Second Amendment to its Loan and Security Agreement with Hercules Capital, Inc., expanding the debt facility to an aggregate of up to $400.0 million. The company immediately borrowed an additional $50.0 million, bringing its total outstanding principal to $200.0 million. The amendment also reduced the minimum cash covenant from 60% to 40% of outstanding obligations and extended its initial testing date, providing increased financial flexibility.

Dyne Therapeutics, Inc. announced an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc., securing up to $125 million in additional borrowing capacity. $50 million was funded immediately, with another $50 million available upon achieving certain milestones and a final $25 million at Hercules Capital's discretion. This additional capital strengthens Dyne's balance sheet, supporting the advancement of its clinical programs, zeleciment rostudirsen and zeleciment basivarsen, through critical clinical and regulatory milestones and preparing for two potential U.S. launches in the next two years.

Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial for zeleciment basivarsen (DYNE-101) in patients with Myotonic Dystrophy Type 1 (DM1). Topline data from this cohort are anticipated in Q1 2027, supporting a potential Biologics License Application (BLA) submission for U.S. Accelerated Approval in Q3 2027. The company aims for a potential U.S. launch of z-basivarsen in H1 2028, pending FDA Priority Review and approval.